Poorly Differentiated Follicular Thyroid Carcinoma: Prognostic Factors and Relevance of Histological Classification

Pulcrano, Melania; Boukheris, Houda; Talbot, Monique; Caillou, Bernard; Dupuy, Corinne; Virion, Alain; Vathaire, Florent de; Schlumberger, Martin

doi:10.1089/thy.2007.0029

Cited by 64 publications

(49 citation statements)

References 41 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The expression of NIS, AIT, Tg, TPO, p138-DUOX, and p53 was evaluated by immunohistochemistry using specific monoclonal or polyclonal antibodies, as previously described (Lacroix et al 2004, Faggiano et al 2007, Pulcrano et al 2007). For GLUT-1 expression, a rabbit polyclonal antibody was used (A3536; dilution 1/200; incubation time: 60 min, Dako, Glostrup, Denmark).…”

Section: Immunohistochemistrymentioning

confidence: 99%

Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?

Deandreis¹,

Ghuzlan²,

Leboulleux³

et al. 2010

Endocrine Related Cancer

155

View full text Add to dashboard Cite

The aim of this study is to search for relationships between histology, radioiodine ( 131 I) uptake, fluorodeoxyglucose (FDG) uptake, and disease outcome in patients with metastatic thyroid cancer. Eighty patients with metastatic thyroid cancer (34 males, 46 females, mean age at the time of the diagnosis of metastases: 55 years) were retrospectively studied. All patients were treated with radioactive iodine and evaluated by FDG-positron emission tomography (PET). Primary tumor tissue sample was available in all cases. Forty-five patients (56%) had a papillary, 12 (15%) a follicular, and 23 (29%) a poorly differentiated thyroid cancer. Cellular atypias, necrosis, mitoses, thyroid capsule infiltration, and vascular invasion were frequently detected (70, 44, 52, 60, and 71% respectively). Metastases disclosed FDG uptake in 58 patients (72%) and 131 I uptake in 37 patients (45%). FDG uptake was the only significant prognostic factor for survival (PZ0.02). The maximum standardized uptake value and the number of FDG avid lesions were also related to prognosis (PZ0.03 and 0.009). Age at the time of the diagnosis of metastases (PZ0.001) and the presence of necrosis (PZ0.002) were independent predictive factors of FDG uptake. Radioiodine uptake was prognostic for stable disease (PZ0.001) and necrosis for progressive disease at 1 year (PZ0.001). Histological subtype was not correlated with in vivo tumor metabolism and prognosis. In conclusion, FDG uptake in metastatic thyroid cancer is highly prognostic for survival. Histological subtype alone does not correlate with 131 I/FDG uptake pattern and patient outcome. Well-differentiated thyroid cancer presenting histological features such as necrosis and FDG uptake on PET scan should be considered aggressive differentiated cancers.

show abstract

Section: Immunohistochemistrymentioning

confidence: 99%

Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?

Deandreis¹,

Ghuzlan²,

Leboulleux³

et al. 2010

Endocrine Related Cancer

155

View full text Add to dashboard Cite

show abstract

“…CDK1 overexpression is also related to carcinoma differentiation (p < 0.0001), and is directly linked to cyclin A overexpression (p < 0.0001), but not to cyclin B1 overexpression (Ito et al, 2002). Cyclin B1 expression does not have any prognostic significance for poorly differentiated follicular thyroid carcinoma (Pulcrano et al, 2007).…”

Section: Thyroid Carcinomamentioning

confidence: 89%

CCNB1 (cyclin B1)

Perez‐Stable¹

2011

Atlas of Genetics and Cytogenetics in Oncology and Haematology

View full text Add to dashboard Cite

IdentityOther names: CCNB HGNC (Hugo): CCNB1 Location: 5q13.2 DNA/RNA Description 9 exons; 2,087 bp; 433 residues CCNB1 transcript 1. 8 exons; 1,833 bp; 397 residues CCNB1 transcript 2. TranscriptionTwo alternative transcripts resulting from distinct transcription initiation sites. One is constitutively expressed and the other is G2/M cell cycle-regulated. PseudogeneNo verified pseudogenes. Protein DescriptionCyclin B1 (48.337 kDa) is a member of the cyclin family of proteins whose levels vary during the cell cycle in order to activate specific cyclin-dependent kinases (CDKs) required for the proper progression through the cell cycle. Cyclin B1 protein begins to increase during G2, peaks in mitosis, and is rapidly degraded before the cell cycle is completed. Cyclin B1 interacts with CDK1 to form a complex known as the maturation-promoting factor (MPF), which is essential for cell cycle progression through mitosis. When chromosomes are properly aligned during anaphase, rapid degradation of cyclin B1 by anaphase-promoting complex/cyclosome (APC/C) is required for mitotic exit and completion of the cell cycle. ExpressionCyclin B1 is overexpressed in a variety of cancers compared to normal cells and tissues. In normal tissues, low levels of cyclin B1 is detected in testis, thymus, bone marrow, and smooth muscle (CCNB1 expression). In most primary tumors, the expression of cyclin B1 is "unscheduled" (unrestricted to particular phases of the cycle), whereas in normal lymphocytes, the expression of cyclin B1 is restricted to very late S and G2 + M phases of the cell cycle (Gorczyca et al., 1997). LocalisationDuring interphase, cyclin B1 is concentrated in the cytoplasm but can shuttle to the nucleus (Pines and Hunter, 1991).Diagram of sequence domains for cyclin B1. The destruction box (DB) is required for degradation of cyclin B1 at the metaphase-toanaphase transition. The cytoplasmic retention sequence (CRS) and the nuclear export signal (NES) are critical determinants of cyclin B1 localization during mitosis. The cyclin box is required for interaction with CDK1.

show abstract

“…Several studies have revealed overexpression of cyclin A and B1 in thyroid cancers, including follicular thyroid carcinoma (FTC), also its poorly differentiated form and thyroid lymphoma [18,19,20]. Mainly, cyclin A has been overexpressed in anaplastic thyroid carcinoma [21].…”

Section: Discussionmentioning

confidence: 99%

Patterns of cyclin A and B1 immunostaining in papillary thyroid carcinoma

Cyniak-Magierska¹,

Stasiak²,

Naze³

et al. 2015

Ann Agric Environ Med.

View full text Add to dashboard Cite

Introduction and objectives. Cyclin A, encoded by CCNA (cyclin A) gene with locus in chromosome 4q27, and cyclin B1, encoded by CCNB1 (cyclin B1) gene with locus in chromosome 5q12, are proteins that play a key role in the passage through the restriction point in G2 phase of the cell cycle. The aim of the study was to analyse immunohistochemically the expression of cyclins A and B1 in different variants of papillary thyroid carcinoma (PTC). Material and methods. The immunostaining patterns of the proteins in question in the tissue of 40 resected PTC (20 cases of classic variant of PTC, 9 cases of PTC follicular variant and 11 cases of other non-classic variants of PTC) were investigated. Results. On analyzing cyclin A and B1 expression, positive staining in 90% cases of PTC were observed. The study revealed a significant difference in expression of cyclins A and B1 between classic and non-classic variants of PTC. The expression of both examined cyclins was weaker in the classic variant of PTC. In the group of follicular variant of PTC, the expression of cyclins was of medium intensity and in the group of other non-classic variants of PTC, the expression was clearly higher. Conclusions.The results of the presented study suggest that cyclins A and B1 expression may have a characteristic pattern of immunostaining for particular variants of PTC. If the obtained results are confirmed in a larger group of patients, the diagnostic panel constructed of the antibodies against these proteins may increase the diagnostic accuracy in PTC cases.

show abstract

Poorly Differentiated Follicular Thyroid Carcinoma: Prognostic Factors and Relevance of Histological Classification

Abstract: PDFC has a more aggressive behavior than well-differentiated carcinomas; prognosis is related to indicators that are also relevant in patients with well-differentiated carcinomas.

Cited by 64 publications

References 41 publications

Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?

Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?

CCNB1 (cyclin B1)

Patterns of cyclin A and B1 immunostaining in papillary thyroid carcinoma

Contact Info

Product

Resources

About